The right bioanalytical partner combines validated assays, regulatory-ready documentation, and the scientific depth to design methods for novel constructs, because bioanalytical testing is critical in developing gene therapies and often requires specialized analytical approaches to generate the safety and efficacy data programs need — ideally under one roof, so data stays consistent from preclinical through clinical.
This guide covers what to look for, the key questions to ask, and why consolidating AAV and lentiviral testing with one partner reduces risk by strengthening gene therapy bioanalytical planning, extending bioanalytical support across the drug development process, and keeping methods aligned as programs advance.
What should you look for when choosing a gene therapy testing partner?
Prioritize partners that offer:
- CLIA-certified, GLP-aligned infrastructure backed by scientific expertise and specialized expertise (Accelevir also aligns to ISO 13485).
- Multiple platforms in-house — dPCR, qPCR, ddPCR, and next-generation sequencing as bioanalytical methods, plus functional immunology (ELISpot/FluoroSpot, flow cytometry)
- End-to-end gene therapy services: assay development, early-program bioanalytical strategy, and method validation to ensure fit-for-purpose assays are specific, sensitive, and accurate.
- Regulatory experience that supports clinical trials, addresses evolving regulatory requirements, and helps teams work with regulatory agencies; validated analytical methods are required for submissions.
- Multi-species and cross-matrix capability, low-input workflows for precious samples, and services tailored to the unique requirements of gene therapies
- A track record — Accelevir has supported 100+ clinical studies with multi-step sample processing paired with complex molecular, genomic, and functional immunology assays underscoring the critical importance of fit-for-purpose assay development for gene therapy success.
What are the key challenges in analytical development for cell and gene therapies?
Novel constructs rarely have off-the-shelf assays, so these unique challenges require fit-for-purpose methods tailored to different gene therapy modalities and viral vectors.
Samples are often low-abundance and precious, demanding high-sensitivity, low-input workflows; cross-species and cross-matrix validation is complex; and regulatory expectations for absolute quantitation are rising, where digital PCR supports absolute quantification of vector genomes with sensitivity approaching single-digit copies per microgram. In AAV gene therapy development, biodistribution studies quantify vector genomes across diverse tissues, reveal off-target transduction patterns, and help assess potential long-term toxicity risks. Regulatory guidelines, including the FDA’s ICH S12 guidance, dictate biodistribution study designs and are central to addressing core bioanalytical challenges. A partner that develops and validates assays to submission standards de-risks each of these, including genome integrity sequencing to detect truncations and rearrangements, confirm intact genetic material, and support therapeutic efficacy. Accelevir also has experience across mouse, NHP, and human samples, so sponsors can carry the same customized assays from preclinical studies through to clinical trial endpoints, a continuity benefit as a program advances.
What questions should you ask a bioanalytical testing partner?
A practical buyer checklist for informed decision-making:
- Are your assays pre-validated, custom, or both?
- Which platforms do you run in-house (dPCR, qPCR, NGS, flow cytometry, ELISpot), and do they support immunogenicity assessment as well as core quantitation?
- How do you monitor immune responses to viral vectors, including pre-existing and induced signals, and how does that data support patient selection?
- Do you assess the risk of neutralizing antibodies in patients, given that these antibodies can reduce efficacy?
- Are you CLIA-certified and GLP-aligned?
- Can you cover both AAV and lentiviral work under one roof?
- What is your experience with IND/BLA submissions and ICH M10 validation?
- How do your regulatory knowledge and bioanalytical strategy support clinical trials, submissions, and eventual product approval?
- What are typical timelines, and how do pre-validated panels and turnaround times for data delivery affect program timelines?
- Is cut-point determination established for cellular immunity assays such as ELISpot?
- Can you handle tech transfer and scale-up toward commercial readiness?
Why does consolidating AAV and lentiviral testing with one partner matter?
Splitting assays across vendors risks inconsistent methods, data gaps, and slower timelines. Consolidating support across gene therapy modalities helps manage regulatory compliance and the safety and efficacy data needed across clinical trials.
For most sponsors the real consolidation benefit is keeping every endpoint their program needs under one roof: molecular assays like genome integrity, vector copy number, biodistribution, and shedding, alongside functional immunology like immunogenicity and flow cytometry, all run in one CLIA-certified laboratory under one quality management system. And for teams working across both AAV and lentiviral vectors, the same partner keeps methods and data consistent from preclinical studies through clinical trials, reducing vendor handoffs in a cost-effective model.